When was Adagene founded?

Adagene was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Adagene located?

Adagene is headquartered in Suzhou, China. It is registered at San Francisco, California.

Who is the current CEO of Adagene?

Peter Luo of Adagene. They have also founded 1 company.

How many employees does Adagene have?

As of Sep 30, 2026, the latest employee count at Adagene is 81.

Is Adagene a funded company?

Adagene is a funded company, having raised a total of $155M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 08, 2014.

When was the latest funding round of Adagene?

Adagene's latest funding was a $***** Post IPO round on Jul 01, 2025, with participation from 1 investor.

Where does Adagene rank among its competitors?

Adagene ranks 42nd amongst 3373 active competitors, of which 1135 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Adagene?

Adagene's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Adagene - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.

Website: www.adagene.com/
Email ID: *****@adagene.com
Phone Number: +86 **********
Registered Address: San Francisco, California

Key Metrics

Founded Year

2012

Location

Suzhou, China

Stage

Public

Total Funding

$155M in 5 rounds

Latest Funding Round

Post IPO, Jul 01, 2025, $*****

Investors

WuXi AppTec & 13 more

Ranked

42^nd among 3373 active competitors

Employee Count

81 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3077 more

Exit Details

Public

View Adagene's full profile

Adagene is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADAGENE INCORPORATED CIN: 822877710 , United States, Active		-	15 (As on Dec 31, 2020)	-

Adagene got listed on Feb 09, 2021.

Click here to take a look at Adagene's IPO in detail

Adagene has raised a total funding of $155M over 5 rounds. Its first funding round was on Dec 08, 2014. Its latest funding round was a Post IPO round on Jul 01, 2025 for $*****. 1 investor participated in its latest round. Adagene has 14 institutional investors.

Here is the list of recent funding rounds of Adagene:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2025	9201515	Post IPO	4675222	3871633	6261862	5964202
Jan 09, 2020	5205126	Series D	6330279	2480450	2925959	Eight Roads Ventures & 3 more
Mar 26, 2018	8207695	Series C	8655262	7242979	Sequoia Capital	New World TMT & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Adagene's funding rounds and investors

The founders of Adagene is Peter Luo. Peter Luo is the CEO of Adagene.

Here are the details of Adagene's key team members:

Peter Luo: Founder & CEO of Adagene and founder of 1 other company.

View details of Adagene's Founder profiles and Board Members

Adagene's employee count trend

Adagene has 81 employees as of Sep 26. Here is Adagene's employee count trend over the years:

Uncover Adagene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adagene include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Adagene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
42nd	Adagene 2012, Suzhou (China), Public	Developer of immunotherapy for the treatment of cancer	$155M	Sanofi, General Atlantic & 12 others	66/100